The Applied Research Of MR Spectroscopy In Prostate Cancer

Objective:To quantitatively evaluate the metabolic changes of prostateadenocarcinoma using magnetic resonance spectroscopy (MRS) .Toevaluate the value of MR spectroscopy in the differential diagnosisof prostate cancer.Methods:53 patients (30 benign prostatic hyperplasia subjects and 23prostate cancer subjects )were performed with the scanning ofmagnetic resonance imaging (MRI)and magnetic resonance spectroscopy(MRS) that have included T1-wighted image and T2-wighted image andchemical shift imaging. the serum PSA detection: Detection with radioimmunoassay. taken suction venous blood 2ml at between 6 and 7 o'clockpreoperative(without 5 a -reducase enzyme inhibitor or other endocrinemedicine,without anipulate through urinary canal or digital rectalexamination), The datum were detected with omniautomatizatingchemoluminescence immunizing set and kit produced by Beckman in U.S.A.after separating the serum. statistical analysis:The numerical dataof prostate spectra and the serum PSA dealed with single factor varianceanalysis and line X array analysis of SPSS 12.0 software. The meansexpressed with X 士S, are significant differences at P<0.05.Results:23 patients performed surgery and histologic classificationof prostate cancer(PCa) was made by two experiencedhistologist( GleasonⅡteam 3 subjects; Gleason Ⅲteam 12 subjects;Gleason Ⅳteam 6 subjects Gleason Ⅴteam 2 subjects) in all 53patients. The spectra of PCa and benign prostatic hyperplasia (BPH)were obtained.We got three definite signals in each group;they areCit ,Cho and Cr. We observed decreased Cit and increased Cho in Prostatecancer. In BPH team, Cho 1.27±0.42 Cr 0.77±0.06 Cit 3.68±0.98Cho/ Cr1.65±0.54 Cho/Cit 0.37±0.12 Cho+Cr / Cit 0.58±0.15;PCateam Cho 3.22±11.12 Cr 0.74±010 Cit 0.54±0.32 Cho/Cr 4.36±1.51Cho/Cit 8.54±8.41Cho+Cr/Cit 10.64±10.09.A significant differenceexists for Cho and Cit BPH team and PCa team(p<0.05);a signicantdifference also exists for the Cho/Cr ratios and Cho+Cr/Cit ratiosbetween BPH team and PCa team(p<0.05).Inspecting prostate specficantigen(PSA) :In BPH team , FPSA 0.93 土0.76 μg/ml TPSA 10.27 土18.72μg/ml FPSA/TPSA 0.15 土0.06; In PCa team, FPSA 10.68 土12.74μg/ml TPSA 1173.93 土211.96μg/ml FPSA/TPSA 0.077 土0.044 . Thereare five grade in Pca : GleasonⅡ+Ⅲteam, Cho 3.42±1.01 Cit 0.67±0.31F-PSA 10.22±14.71 T-PSA 170.4±233.4 CC/C 7.59±3.71 F/T0.080±0.049 GleasonⅣ+Ⅴcho2.84±1.89 cit0.31±0.19 F-PSA 9.08±7.92 T-PSA180.53±179.23 CC/C16.37±15.33 F/T0.074±0.036. There isreliable correlation of line between Cit,Cho+Cr/Cit and PSA ,F/Tin the grade of prostate cancer .Conclusions:1,MR imaging has become an important tool in the location and diagnosisof Prostate Cancer,but when the grading and evaluation of prostatecancer is concerned,its ability is limited.2,Proton MR spectroscopy has made it possible to obtain functionaland metabolic information about prostate cancer non-invasively. It issuggests that MRS play a role in the diagnosis and differentialdiagnosis and the grading and evaluation.3 ,connection MR spectroscopy of prostate with prostate specficantigen(PSA) may improve the specific and the differential in thediagnotic prostate cancer.